| Applications: |
Immunodepletion/Immunocompetition |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
RIPK3 Blocking Peptide for STJ502806 is synthetically produced from the 461-511 sequence and is suitable for use in western blot applications. |
| Formulation: |
Liquid form at 2.5mg/ml concentration in PBS. Up to 5% DMSO can be added. Orders with >1mg can be supplied in lyophilized powder form, or in buffer of choice. |
| Storage Instruction: |
Store at-20°C for long term storage. Avoid freeze-thaw cycles. |
| Gene Symbol: |
RIPK3 |
| Gene ID: |
11035 |
| Uniprot ID: |
RIPK3_HUMAN |
| Immunogen Region: |
461-511 |
| Specificity: |
This blocking peptide is recommended for use in combination with RIPK3 antibody, STJ502806 |
| Immunogen: |
Synthetic peptide taken within amino acid region 461-511 on human Receptor-interacting Serine/Threonine-protein kinase 3 protein. |
| Tissue Specificity | Highly expressed in the pancreas. Detected at lower levels in heart, placenta, lung and kidney. Isoform 3: Expression is significantly increased in colon and lung cancers. |
| Post Translational Modifications | (Microbial infection) Proteolytically cleaved by S.flexneri OspD3 within the RIP homotypic interaction motif (RHIM), leading to its degradation and inhibition of necroptosis. RIPK1 and RIPK3 undergo reciprocal auto- and trans-phosphorylation. Autophosphorylated following interaction with ZBP1. Phosphorylation of Ser-199 plays a role in the necroptotic function of RIPK3. Autophosphorylates at Ser-227 following activation by ZBP1: phosphorylation at these sites is a hallmark of necroptosis and is required for binding MLKL. Phosphorylation at Thr-182 is important for its kinase activity, interaction with PELI1 and PELI1-mediated 'Lys-48'-linked polyubiquitination and for its ability to mediate TNF-induced necroptosis. Polyubiquitinated with 'Lys-48' and 'Lys-63'-linked chains by BIRC2/c-IAP1 and BIRC3/c-IAP2, leading to activation of NF-kappa-B. Polyubiquitinated with 'Lys-48'-linked chains by PELI1 leading to its subsequent proteasome-dependent degradation. Ubiquitinated by STUB1 leading to its subsequent proteasome-dependent degradation. |
| Function | Serine/threonine-protein kinase that activates necroptosis and apoptosis, two parallel forms of cell death. Necroptosis, a programmed cell death process in response to death-inducing TNF-alpha family members, is triggered by RIPK3 following activation by ZBP1. Activated RIPK3 forms a necrosis-inducing complex and mediates phosphorylation of MLKL, promoting MLKL localization to the plasma membrane and execution of programmed necrosis characterized by calcium influx and plasma membrane damage. In addition to TNF-induced necroptosis, necroptosis can also take place in the nucleus in response to orthomyxoviruses infection: following ZBP1 activation, which senses double-stranded Z-RNA structures, nuclear RIPK3 catalyzes phosphorylation and activation of MLKL, promoting disruption of the nuclear envelope and leakage of cellular DNA into the cytosol. Also regulates apoptosis: apoptosis depends on RIPK1, FADD and CASP8, and is independent of MLKL and RIPK3 kinase activity. Phosphorylates RIPK1: RIPK1 and RIPK3 undergo reciprocal auto- and trans-phosphorylation. In some cell types, also able to restrict viral replication by promoting cell death-independent responses. In response to Zika virus infection in neurons, promotes a cell death-independent pathway that restricts viral replication: together with ZBP1, promotes a death-independent transcriptional program that modifies the cellular metabolism via up-regulation expression of the enzyme ACOD1/IRG1 and production of the metabolite itaconate. Itaconate inhibits the activity of succinate dehydrogenase, generating a metabolic state in neurons that suppresses replication of viral genomes. RIPK3 binds to and enhances the activity of three metabolic enzymes: GLUL, GLUD1, and PYGL. These metabolic enzymes may eventually stimulate the tricarboxylic acid cycle and oxidative phosphorylation, which could result in enhanced ROS production. (Microbial infection) In case of herpes simplex virus 1/HHV-1 infection, forms heteromeric amyloid structures with HHV-1 protein RIR1/ICP6 which may inhibit RIPK3-mediated necroptosis, thereby preventing host cell death pathway and allowing viral evasion. |
| Peptide Name | Receptor-Interacting Serine/Threonine-Protein Kinase 3Rip-Like Protein Kinase 3Receptor-Interacting Protein 3Rip-3 |
| Database Links | Reactome: R-HSA-168927Reactome: R-HSA-1810476Reactome: R-HSA-2562578Reactome: R-HSA-3295583Reactome: R-HSA-5213460Reactome: R-HSA-5675482Reactome: R-HSA-9013957Reactome: R-HSA-937041Reactome: R-HSA-9686347Reactome: R-HSA-9692913Reactome: R-HSA-9692916 |
| Cellular Localisation | CytoplasmCytosolNucleusMainly CytoplasmicPresent In The Nucleus In Response To Influenza A Virus (Iav) Infection |
| Alternative Peptide Names | Receptor-Interacting Serine/Threonine-Protein Kinase 3 proteinRip-Like Protein Kinase 3 proteinReceptor-Interacting Protein 3 proteinRip-3 proteinRIPK3 proteinRIP3 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
